Patent echoes for Viralytics
Monday, 30 March, 2009
Sydney company Viralytics has received a patent in the US for its range of echoviruses, which aim to bind to and infect cancer cells.
The echovirus type 1 (EV1) binds to cells expressing integrin alpha2 beta 2, a receptor on the cell surface receptor highly expressed in some cancers, particularly prostate, ovarian and gastric tumours.
Viralytics has a proprietary formulation of EV1 called Evatak, as well as a formulation for a subset of coxsackie A viruses called Cavatak. Cavatak binds to the receptors intercellular adhesion molecule-1 and decay accelerating factor.
The company is running Phase I trials of Cavatak in melanoma, prostate, breast and head and neck cancers.
No clear link between paracetamol in pregnancy and autism/ADHD
Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
